In order to achieve our mission, we partner with leading biotechnology companies, pharmaceutical companies and academic research institutions to identify novel therapeutics and unlock biological insights using our discovery technology. Our partnering efforts take two primary forms: discovery platform partnerships and asset development partnerships.
We have collaborated with third parties to broadly explore diverse disease domains (e.g., fibrosis, neuroscience, oncology, immunology, and inflammation) in order to identify potential therapeutics. While our partnerships to date have focused on small molecule research, future partnerships may extend into large molecules and novel therapeutic modalities including gene therapies and cell therapies.
The goal of every partnership is to create therapeutics, yet the approach may take multiple forms:
Without any presumptive target hypothesis, we can identify differentiated potential therapeutics by rapidly evaluating large (hundreds to hundreds of thousands) compound libraries alongside existing or de novo disease models informed by our partner’s subject matter expertise
By profiling diverse biological perturbations (e.g., genetic, soluble factors) on our platform, we may be able to identify novel druggable targets that we can then exploit with partners to generate potential therapeutic candidates
In August 2020, we entered into a multi-year, strategic collaboration with Bayer in the area of fibrosis, which we expanded in December 2021 to include our powerful inferential search capabilities. Under the updated partnership, we may initiate more than a dozen programs to identify novel therapeutics for devastating and complex fibrotic diseases across multiple organ systems including lung, liver and heart. Bayer has contributed approximately 500,000 compounds from its proprietary library and is providing deep scientific expertise to the collaboration.
In December 2021, we entered into a multi-year, strategic collaboration with Roche and Genentech in key areas of neuroscience and an oncology indication. Through the partnership, we are working with both Roche and Genentech's R&D units to leverage our Recursion OS and Maps of Biology, along with extensive single-cell perturbation screening data from Roche and Genentech, to rapidly identify novel biological relationships to initiate and advance therapeutic programs. Together we may initiate up to 40 programs over a decade or longer.
In addition to NCEs, the Recursion Map may discover new uses for known chemical entities owned or controlled by third parties. In such circumstances, we may in-license rights to these assets to advance these programs internally.
Connect with us at partner@recursionpharma.com.
